AIM ImmunoTech Inc. (AIM): Nasdaq/NYSE listing notice — AIM ImmunoTech receives NYSE American delisting notice for low stock price; plans appeal

AIM ImmunoTech Inc.

Received notice on April 4, 2025 from NYSE American of suspension and delisting under Section 1003(f)(v) due to low selling price.
Company will appeal the delisting determination to the Listing Qualifications Panel; no guarantee of success.
Common stock expected to begin trading on the Pink Open Market on April 7, 2025.
Trading on NYSE American has been suspended effective April 4, 2025.

item 3.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

AIM ImmunoTech Inc. received a nyse_american delisting notice notice regarding minimum bid price (rules 1003(f)(v)).

Exchange: nyse american
Notice: delisting notice
Deficiency: minimum bid price
Rules: 1003(f)(v)

Exact text from the filing

April 4, 2025, AIM ImmunoTech Inc. (the “Company”) received notice from NYSE Regulation of the NYSE American LLC (“NYSE American”) that it had suspended trading of the Company’s common stock and determined to commence proceedings to delist the Company’s common stock from the NYSE American as a result of its determination that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Company’s common stock. The Company has a right to a review of NYSE American’s determination to delist the Company’s common

View on SEC.gov

50 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

AIM ImmunoTech Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-002858

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.